Cardinal Health, Inc.

🇺🇸New York Stock Exchange
Back to all articles
Cardinal Health, Inc. stock analysis CAH overview
Somewhat Bullish +50

Is It Too Late To Consider Cardinal Health (CAH) After Its Strong Multi‑Year Share Price Run?

📉 Cardinal Health (CAH) shares recently declined 0.5% over the last month following a strong 48.7% return over the past year and a 272% gain over five years.

💰 A Discounted Cash Flow (DCF) model estimates an intrinsic value of approximately $540.74 per share, suggesting the stock is undervalued by 62% compared to the current price of ~$205.

📊 The company trades at a P/E ratio of 29.11x, which is above both the healthcare industry average (24.34x) and peer averages (24.47x).

🎯 Simply Wall St's proprietary "Fair Ratio" model determines a fair P/E of 31.16x, indicating the current shares trade below their modeled valuation level.

💧 Cardinal Health is projected to generate free cash flow of $5.52b in the last twelve months, growing to $4.75b by 2030 according to the DCF assumptions.

🤝 The stock price has stabilized recently as investors reassess risks and long-term demand within the healthcare supply chain sector.

🧠 Valuation analysis incorporates company-specific fundamentals such as earnings growth profiles and profit margins rather than relying solely on broad industry averages.

💬 Community narratives show divergent investor expectations, with bullish targets up to $275 contrasting against more cautious targets around $200.

⚠️ The article includes a standard disclaimer stating the content is based on historical data and analyst forecasts and does not constitute financial advice.

Bullish Signals
  • Cardinal Health has delivered a strong 48.7% return over the last year and an impressive 162.3% return over the past three years.
  • A Discounted Cash Flow model estimates Cardinal Health's intrinsic value at $540.74 per share, implying the stock is 62.0% undervalued compared to the current price of roughly $205.
  • Simply Wall St's proprietary Fair Ratio for Cardinal Health is 31.16x, which is higher than the company's current P/E of 29.11x, suggesting the shares trade below their modeled fair value level.
  • Analyst forecasts have generated bullish price targets as high as US$275 per share, indicating potential upside for investors.
Risk Factors
  • The stock experienced a decline of 0.5% over the last 30 days, indicating short-term weakness despite long-term gains.
  • Analysts are currently predicting price targets as high as US$275, while other cautious views project targets around US$200, highlighting significant valuation uncertainty among market participants.
  • The P/E ratio of 29.11x is noted to be above both the Healthcare industry average of 24.34x and the peer average of 24.47x, suggesting the stock may be priced higher than its peers despite undervaluation metrics.
Full Analysis
Cardinal Health (CAH) recently traded around US$205 per share, marking a 48.7% gain over the last year and a massive 162.3% return over the past three years after a total five-year run of 272%. Simply Wall St analyzes whether this strong price appreciation has fully priced in the company's future potential or if there is still value to be captured, noting recent share price steadiness with minimal movement over the last few weeks. The analysis utilizes a Discounted Cash Flow (DCF) model starting from a free cash flow of approximately $5.52 billion for the trailing twelve months. By projecting future cash flows through 2035 and discounting them back to present value, the DCF model estimates an intrinsic share value of roughly $540.74, implying the stock is currently undervalued by 62% based on these specific assumptions and a two-stage free cash flow to equity approach. Valuation metrics including the Price-to-Earnings ratio are also examined, showing CAH trading at a P/E of 29.11x. This figure is compared against the Healthcare industry average of 24.34x and peer averages around 24.47x, though Simply Wall St's proprietary Fair Ratio model suggests a fair P/E of 31.16x based on earnings growth, margins, and risk factors. The current trading price is considered below this tailored Fair Ratio, further supporting the undervaluation thesis derived from the DCF model. The article concludes by highlighting that different investors may hold varying views represented in the community, ranging from bullish analyst price targets up to US$275 to more cautious estimates around US$200. Simply Wall St notes its analysis relies on historical data and forecasts without taking into account the latest price-sensitive company announcements or qualitative material, serving as a general informational piece rather than direct financial advice to buy or sell the stock.